Speaker Details

speaker photo

John McCamant


Medical Technology Stock Letter


John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

Content from John McCamant

Keyword Image
Top Picks 2021: Vaxart (VXRT)
01/08/2021 5:30 am EST

Vaxart (VXRT) is a leader in developing an oral vaccine for COVID-19 that would make it significantl...